Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001641172-25-004585
Filing Date
2025-04-14
Accepted
2025-04-14 16:45:18
Documents
21
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 formdef14a.htm   iXBRL DEF 14A 701540
2 def14a_001.jpg GRAPHIC 38906
3 def14a_002.jpg GRAPHIC 37472
4 def14a_004.jpg GRAPHIC 28349
5 proxy_001.jpg GRAPHIC 954588
6 proxy_002.jpg GRAPHIC 509709
  Complete submission text file 0001641172-25-004585.txt   5064899

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE erna-20241231.xsd EX-101.SCH 6166
8 XBRL DEFINITION FILE erna-20241231_def.xml EX-101.DEF 10689
9 XBRL LABEL FILE erna-20241231_lab.xml EX-101.LAB 65200
10 XBRL PRESENTATION FILE erna-20241231_pre.xml EX-101.PRE 43292
23 EXTRACTED XBRL INSTANCE DOCUMENT formdef14a_htm.xml XML 166784
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (617) 798-6700
Ernexa Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-11460 | Film No.: 25836505
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)